.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Federal Trade Commission
Chinese Patent Office
Cerilliant
Argus Health
Daiichi Sankyo
McKinsey
Baxter
Novartis

Generated: September 22, 2017

DrugPatentWatch Database Preview

BINOSTO Drug Profile

« Back to Dashboard

Which patents cover Binosto, and when can generic versions of Binosto launch?

Binosto is a drug marketed by Mission Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has ten patent family members in seven countries.

The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.

Summary for Tradename: BINOSTO

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list25
Clinical Trials: see list1
Patent Applications: see list4,882
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:BINOSTO at DailyMed

Pharmacology for Tradename: BINOSTO

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mission Pharma
BINOSTO
alendronate sodium
TABLET, EFFERVESCENT;ORAL202344-001Mar 12, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Mission Pharma
BINOSTO
alendronate sodium
TABLET, EFFERVESCENT;ORAL202344-001Mar 12, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: BINOSTO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,449,906Effervescent compositions comprising phosphonates and methods related thereto► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BINOSTO

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004035004► Subscribe
Austria541575► Subscribe
World Intellectual Property Organization (WIPO)03075884► Subscribe
Denmark1490024► Subscribe
Australia2003284275► Subscribe
European Patent Office1490024► Subscribe
Spain2448501► Subscribe
Spain2380924► Subscribe
Australia2003219999► Subscribe
Canada2495886► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Harvard Business School
AstraZeneca
QuintilesIMS
Julphar
Fuji
Healthtrust
Fish and Richardson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot